Disparities in Timeliness of Endometrial Cancer Care: A Scoping Review.

We use the person-centered Pathway to Treatment framework to assess the scope of evidence on disparities in endometrial cancer stage at diagnosis. This report is intended to facilitate interventions, research, and advocacy that reduce disparities. We completed a structured search of electronic databases: PubMed, EMBASE, Scopus, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials databases. Included studies were published between January 2000 and 2023 and addressed marginalized population(s) in the United States with the ability to develop endometrial cancer and addressed variable(s) outlined in the Pathway to Treatment. Our database search strategy was designed for sensitivity to identify studies on disparate prolongation of the Pathway to Treatment for endometrial cancer, tallying 2,171. Inclusion criteria were broad, yet only 24 studies addressed this issue. All articles were independently screened by two reviewers. Twenty-four studies were included: 10 on symptom appraisal, five on help seeking, five on diagnosis, and 10 on pretreatment intervals. Quality rankings were heterogeneous, between 3 and 9 (median 7.2) per the Newcastle-Ottawa Scale. We identified three qualitative, two participatory, and two intervention studies. Studies on help seeking predominantly investigate patient-driven delays. When disease factors were controlled for, delays of the pretreatment interval were independently associated with racism toward Black and Hispanic people, less education, lower socioeconomic status, and nonprivate insurance. Evidence gaps on disparities in timeliness of endometrial cancer care reveal emphasis of patient-driven help-seeking delays, reliance on health care-derived databases, underutilization of participatory methods, and a paucity of intervention studies. Given that PROSPERO was not accepting systematic scoping review protocols at the time this study began, this study protocol was shared a priori through Open Science Framework on January 13, 2021 (doi: 10.17605/OSF.IO/V2ZXY), and through peer review publication on April 13, 2021 (doi: https://doi.org/10.1186/s13643-021-01649-x).

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

Financial Disclosure Jamie N. Bakkum-Gamez disclosed that money was paid to their institution from the following: NIH/NCI—P30CA15083 (PI: Willman); V Foundation grant—T2016-001-03 (PI: Bakkum-Gamez); and NIH/NCI—CA136393 (PI: Kaufmann). They also disclosed the following: Exact Sciences–contracted research agreement between Mayo Clinic and Exact 5. They are listed as an inventor on IP that is licensed by both Exact and Mayo Clinic and received no royalties to date. They are a member of the Foundation for Women's Cancer Board of Directors. Andrew M. Kaunitz received payment from Myovant. He authored chapters in the e-textbook for UpToDate on Contraception, Abnormal Uterine Bleeding, Dysmenorrhea, and Menstrual Suppression. Avonne E. Connor has been a grant reviewer for the American Cancer Society. Christopher C. Destephano received payment from Abiomed, purchased by Johnson and Johnson, stock therefore became cash. Transferred as gift from parent. Family is an important influence on my work but the gift is unrelated to the manuscript submitted. Mark Sherman receives support from Exact Sciences for cancer detection research. The other authors did not report any potential conflicts of interest.